Healthy
Male
>7 Metabolic Equivalents
Written informed consent
Chronic pain syndrome
Drug abuse
Alcohol abuse
Suspicion of neurologic dysfunction at tested sites
Ongoing treatment with antidepressants
Ongoing treatment with analgesics
Pretreatment with any CYP3A inducers or inhibitors
Known allergy to tested drugs
Elevated eye pressure
Obstructive uropathy
Heart disease
Pulmonary disease
Neurological disease
Psychiatric illness

NCT02256943_inc_T1
Condition
Healthy
NCT02256943_inc_T2
Person
Male
NCT02256943_inc_T3
Value
>7
NCT02256943_inc_T4
Measurement
Metabolic Equivalents
NCT02256943_inc_T6
Condition
Chronic pain syndrome
NCT02256943_inc_T7
Condition
Drug abuse
NCT02256943_inc_T8
Condition
Alcohol abuse
NCT02256943_inc_T9
Mood
Suspicion
NCT02256943_inc_T10
Condition
neurologic dysfunction
NCT02256943_inc_T11
Qualifier
tested sites
NCT02256943_inc_T12
Temporal
Ongoing
NCT02256943_inc_T13
Procedure
treatment
NCT02256943_inc_T14
Drug
antidepressants
NCT02256943_inc_T15
Temporal
Ongoing
NCT02256943_inc_T16
Procedure
treatment
NCT02256943_inc_T17
Drug
analgesics
NCT02256943_inc_T18
Procedure
Pretreatment
NCT02256943_inc_T19
Drug
CYP3A inducers
NCT02256943_inc_T20
Drug
cers 
Known al
NCT02256943_inc_T21
Scope
CYP3A inducers or inhibitors
NCT02256943_inc_T22
Condition
allergy
NCT02256943_inc_T23
Drug
tested drugs
NCT02256943_inc_T24
Condition
Elevated eye pressure
NCT02256943_inc_T25
Condition
Obstructive uropathy
NCT02256943_inc_T26
Condition
Heart disease
NCT02256943_inc_T27
Condition
Pulmonary disease
NCT02256943_inc_T28
Condition
Neurological disease
NCT02256943_inc_T29
Condition
Psychiatric illness